Literatur
Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Overvad K (2002) European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 5(6b):1113–1124
Taniguchi M, Okazaki T (2014) The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration—from cell and animal models to human disorders. Biochim Biophys Acta 1841(5):692–703
Kühn T, Floegel A, Sookthai D, Johnson T, Rolle-Kampczyk U, Otto W, Kaaks R et al (2016) Higher plasma levels of lysophosphatidylcholine 18: 0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Med 14(1):13
Shu X, Xiang YB, Rothman N, Yu D, Li HL, Yang G, Jia W (2018) Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer 143(3):527–534
Fages A, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, Clavel-Chapelon F (2015) Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med 13(1):242
Boyd LK, Mao X, Lu YJ (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 9(11):652
Adams CD et al (2019) Circulating metabolic biomarkers of screen-detected prostate cancer in the ProtecT study. Cancer Epidemiol Biomarkers Prev 1(28):208–216
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Kalogirou und M. Krebs geben an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Kalogirou, C., Krebs, M. Metabolisches Profiling und Prostatakarzinomrisiko: Chance für „liquid biopsies“?. Urologe 59, 839–840 (2020). https://doi.org/10.1007/s00120-020-01225-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-020-01225-6